MS Living Well: Key Info from Multiple Sclerosis Experts

Many people living with multiple sclerosis are interested in whether vitamins, supplements, or nutrition can play a supportive role in long-term brain and immune health. Two areas that have received growing research attention are alpha-linolenic acid, a plant-based omega-3 fatty acid found in foods like flaxseed and walnuts, and vitamin D, a hormone-like nutrient involved in immune regulation that is often low in people with MS. With so much information online, it can be difficult to know what is truly supported by research versus what is based on personal stories or assumption. New studies are helping us understand these topics more clearly. We explore new insights from large-scale cohort studies and randomized clinical trials assessing the potential role of alpha-linolenic acid and high-dose vitamin D supplementation in early MS. Biomarker-based findings show an association between higher alpha-linolenic acid levels and reduced relapse risk and disability progression over long-term follow-up. The D-Lay MS trial demonstrated a reduction in disease activity in people living with MS receiving high-dose vitamin D early in their condition. Jamie Holloman MD, neurologist at The MS Center for Innovations in Care, interviews: Marianna Cortese MD PhD, Senior Research Scientist, Department of Nutrition at Harvard T.H. Chan School of Public Health Professor Éric Thouvenot, Head of the Neurology Department, Nîmes University Hospital, France

CAR-T therapy, short for chimeric antigen receptor T-cell therapy, is already transforming treatment for blood cancers like lymphoma and leukemia and is now being tested in early trials for multiple sclerosis. In this approach, a person's own T cells (or sometimes donor T cells) are collected and reengineered in the lab with a special "chimeric" receptor on their surface. Once infused back into the body, these "designer" T cells can specifically hunt down B cells, including those hiding in the brain and spinal cord that may drive progressive MS. This is a key difference since current B-cell depleting antibody treatments don't reach effectively into the central nervous system. Like any powerful therapy, CAR-T is not without risks. Side effects can include serious infections, cytokine release syndrome (fever, chills, body aches), and even neurological symptoms like confusion or seizures. Still, the early results in MS patients are remarkable, bringing fresh hope for those with progressive disease. Beyond MS, CAR-T is being explored across autoimmune neurological diseases from myasthenia gravis to stiff person syndrome, opening a promising new frontier in care. Barry Singer MD, Director of the MS Center for Innovations in Care, interviews: Jeffrey Dunn MD, Clinical Professor and Chief of Neuroimmunology in the Department of Neurology & Neurological Sciences at Stanford University Amanda Piquet MD, Professor of Neurology and Céline Dion Foundation Endowed Chair at the University of Colorado Anschutz School of Medicine

The quest to repair the damage caused by multiple sclerosis is gaining momentum, with scientists working to restore lost function and slow progression by rebuilding myelin—the protective coating of nerve cells. Within the brain and spinal cord, immature myelin-making cells called OPCs hold promise, but need the right signals to mature into oligodendrocytes and repair MS lesions. Researchers are also studying the role of microglia, the immune cells that clear debris but can turn destructive, with drugs like BTK inhibitors potentially tilting them toward repair. Early attempts at remyelination drugs such as opicinumab and elezanumab showed promise in animals but ultimately failed in human trials, underscoring the challenge. Still, reasons for optimism are emerging: clemastine, a common antihistamine, showed signs of remyelination in optic neuritis, while PIPE-307—a compound inspired by green mamba snake venom—is in Phase 2 trials. Even novel approaches like gold nanoparticles are being studied to boost oligodendrocyte energy and repair capacity. The path is complex, but progress is accelerating—bringing remyelination therapies closer to becoming a real option for people living with MS. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews: Veronique Miron PhD, MS Research Chair at St. Michael's Hospital and Professor of Immunology at The University of Toronto Robert Glanzman MD, Board-certified neurologist and Chief Medical Officer of Find Therapeutics

Parenting can be both a beautiful adventure and a demanding test. For those living with multiple sclerosis, the joys of raising children often come with added challenges—fatigue, changes in routine, and questions about how MS may affect family life. Despite these obstacles, many parents with MS find that their journey brings deeper meaning, resilience, and joy. In this podcast episode, we'll explore the unique challenges and strengths of parenting with MS. From managing invisible symptoms to navigating conversations with children, our guests share their expertise and experience to provide guidance and encouragement for families. Dr. Jamie Holloman, neurologist at the MS Center for Innovations in Care at Missouri Baptist Medical Center, interviews: Amy Sullivan PsyD, Clinical Health Psychologist, Director of Behavioral Medicine at the Cleveland Clinic Mellen Center for Multiple Sclerosis. Julie Stamm, MS advocate and author of Some Days: A Tale of Love, Ice Cream, and My Mom's Chronic Illness.

Stem cells have the extraordinary ability to transform into different types of cells and renew themselves—offering new hope in the treatment of multiple sclerosis. One of the most advanced approaches—autologous hematopoietic stem cell transplantation (AHSCT)—involves collecting a patient's own bone marrow stem cells, using chemotherapy to wipe out their faulty immune system, and then reinfusing the stem cells to help rebuild it. A more aggressive "myeloablative" approach can effectively halt relapses and new MRI activity but carries serious risks, including life-threatening infections. A gentler "immunoablative" method reduces these risks but allows for a return of MS activity in up to 25% of patients. AHSCT is typically reserved for younger individuals with aggressive relapsing disease and moderate or milder disability. Mesenchymal stem cells—derived from fat, bone marrow support tissue, or dental pulp—have shown mixed results. A large international trial found no benefit when delivered intravenously, although the treatment was safe. However, a smaller study using repeated injections into the spinal fluid showed disease stabilization in most participants. New research is now exploring neural stem cells, which may help protect and repair the brain and spinal cord. A recent Phase 1 trial involving 15 people with secondary progressive MS found reduced inflammation in blood and spinal fluid markers and less brain shrinkage on MRI scans following neural stem cells given into the spinal fluid spaces of the brain. Tune in as we unpack the science, the risks, and the exciting future of stem cell therapies in MS. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews: Stefano Pluchino MD PhD, Clinical Professor of Regenerative Neuroimmunology, Honorary Consultant in Neurology, University of Cambridge, UK Mark Freedman MD, Professor of Medicine in the field of neurology, University of Ottawa, and Director of the Multiple Sclerosis Research Unit, Ottawa Hospital, Canada